BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 31002604)

  • 1. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
    Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
    Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
    Chouaib S
    Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy.
    Abou Khouzam R; Goutham HV; Zaarour RF; Chamseddine AN; Francis A; Buart S; Terry S; Chouaib S
    Semin Cancer Biol; 2020 Oct; 65():140-154. PubMed ID: 31927131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
    Chouaib S; Noman MZ; Kosmatopoulos K; Curran MA
    Oncogene; 2017 Jan; 36(4):439-445. PubMed ID: 27345407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
    Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
    Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-/HIF-1α-Driven Factors of the Tumor Microenvironment Impeding Antitumor Immune Responses and Promoting Malignant Progression.
    Vaupel P; Multhoff G
    Adv Exp Med Biol; 2018; 1072():171-175. PubMed ID: 30178341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets.
    Ray SK; Mukherjee S
    Curr Drug Targets; 2022; 23(5):471-485. PubMed ID: 35021970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges.
    Noman MZ; Hasmim M; Lequeux A; Xiao M; Duhem C; Chouaib S; Berchem G; Janji B
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced nanotechnology for hypoxia-associated antitumor therapy.
    Zhao L; Fu C; Tan L; Li T; Zhong H; Meng X
    Nanoscale; 2020 Feb; 12(5):2855-2874. PubMed ID: 31965135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity.
    Terry S; Faouzi Zaarour R; Hassan Venkatesh G; Francis A; El-Sayed W; Buart S; Bravo P; Thiery J; Chouaib S
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
    Janji B; Berchem G; Chouaib S
    Front Immunol; 2018; 9():887. PubMed ID: 29922284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting hypoxic tumor microenvironment in pancreatic cancer.
    Tao J; Yang G; Zhou W; Qiu J; Chen G; Luo W; Zhao F; You L; Zheng L; Zhang T; Zhao Y
    J Hematol Oncol; 2021 Jan; 14(1):14. PubMed ID: 33436044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
    Shevchenko I; Bazhin AV
    Front Immunol; 2018; 9():1816. PubMed ID: 30131808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.
    Abou Khouzam R; Brodaczewska K; Filipiak A; Zeinelabdin NA; Buart S; Szczylik C; Kieda C; Chouaib S
    Front Immunol; 2020; 11():613114. PubMed ID: 33552076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?
    Abou Khouzam R; Zaarour RF; Brodaczewska K; Azakir B; Venkatesh GH; Thiery J; Terry S; Chouaib S
    Front Immunol; 2022; 13():828875. PubMed ID: 35211123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.
    Noman MZ; Hasmim M; Messai Y; Terry S; Kieda C; Janji B; Chouaib S
    Am J Physiol Cell Physiol; 2015 Nov; 309(9):C569-79. PubMed ID: 26310815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.
    Wang B; Zhao Q; Zhang Y; Liu Z; Zheng Z; Liu S; Meng L; Xin Y; Jiang X
    J Exp Clin Cancer Res; 2021 Jan; 40(1):24. PubMed ID: 33422072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
    Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
    Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.